mTOR: Role in cancer, metastasis and drug resistance

AK Murugan - Seminars in cancer biology, 2019 - Elsevier
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that gets inputs from
the amino acids, nutrients, growth factor, and environmental cues to regulate varieties of …

Eukaryotic translation initiation factors as promising targets in cancer therapy

P Hao, J Yu, R Ward, Y Liu, Q Hao, S An… - Cell Communication and …, 2020 - Springer
The regulation of the translation of messenger RNA (mRNA) in eukaryotic cells is critical for
gene expression, and occurs principally at the initiation phase which is mainly regulated by …

Transcriptome profiling reveals that VNPP433‐3β, the lead next‐generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial …

E Thomas, RS Thankan… - Molecular …, 2022 - Wiley Online Library
Cancer stem cells (CSCs) virtually present in all tumors albeit in small numbers are primarily
responsible for driving cancer progression, metastasis, drug resistance, and recurrence …

Update on the development of MNK inhibitors as therapeutic agents

W Xu, S Kannan, CS Verma… - Journal of medicinal …, 2021 - ACS Publications
Mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1/2) represent a central
class of enzymes that are activated by extracellular signal-regulated kinase (ERK) or p38 …

Progress in developing MNK inhibitors

X Jin, R Yu, X Wang, CG Proud, T Jiang - European Journal of Medicinal …, 2021 - Elsevier
The MNKs (mitogen-activated protein kinase-interacting protein kinases) phosphorylate
eIF4E (eukaryotic initiation factor 4 E) at serine 209; eIF4E plays an important role in the …

[HTML][HTML] N7-methylguanosine modification: from regulatory roles to therapeutic implications in cancer

M Cai, C Yang, Z Wang - American Journal of Cancer Research, 2023 - ncbi.nlm.nih.gov
Abstract N7-methylguanosine (m7G) is one of the most common post-transcriptional
epigenetic modifications. Different m7G methyltransferases (writers) load the m7G-cap at the …

Novel AR/AR-V7 and Mnk1/2 degrader, VNPP433-3β: molecular mechanisms of action and efficacy in AR-overexpressing castration resistant prostate cancer in vitro …

E Thomas, RS Thankan, P Purushottamachar… - Cells, 2022 - mdpi.com
Prostate cancer (PCa) relies in part on AR-signaling for disease development and
progression. Earlier, we developed drug candidate galeterone, which advanced through …

Exploring the role of m7G modification in Cancer: Mechanisms, regulatory proteins, and biomarker potential

Y Zhang, W Xu, C Peng, S Ren, SM Hidig, C Zhang - Cellular Signalling, 2024 - Elsevier
Abstract The dysregulation of N (7)-methylguanosine (m7G) modification is increasingly
recognized as a key factor in the pathogenesis of cancers. Aberrant expression of these …

MNK, mTOR or eIF4E-selecting the best anti-tumor target for blocking translation initiation

S Li, J Chen, X Li, D Shi - European Journal of Medicinal Chemistry, 2023 - Elsevier
Overexpression of eIF4E is common in patients with various solid tumors and hematologic
cancers. As a potential anti-cancer target, eIF4E has attracted extensive attention from …

m7G-related gene NUDT4 as a novel biomarker promoting cancer cell proliferation in lung adenocarcinoma

Y Liu, B Jiang, C Lin, W Zhu, D Chen, Y Sheng… - Frontiers in …, 2023 - frontiersin.org
Background Lung cancer is the leading cause of mortality in cancer patients. N7-
methylguanosine (m7G) modification as a translational regulation pattern has been reported …